Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198496 | 0.91 | ALDH1A1 (0.57) | CYP1A2CYP2D6ALDH1A1LMNAMAPT | |
| SCHEMBL29082481 | 0.89 | CYP1A2 (0.47) | CYP1A2CYP2D6ALDH1A1LMNAMAPT | |
| SCHEMBL29157993 | 0.86 | DRD2 (0.52) | ALDH1A1DRD2MGLL | |
| SCHEMBL29931283 | 0.85 | ALDH1A1 (0.52) | CYP1A2CYP2D6ALDH1A1LMNAMAPT | |
| SCHEMBL29067082 | 0.84 | EPHX2 (0.59) | ALDH1A1LMNADRD2MGLL | |
| SCHEMBL392783 | 0.82 | ALDH1A1 (0.72) | CYP1A2CYP2D6ALDH1A1LMNAMAPT | |
| SCHEMBL1815044 | 0.82 | MAPT (0.61) | ALDH1A1LMNAMAPTDRD2 | |
| SCHEMBL5200907 | 0.81 | KMT2A (0.57) | CYP1A2CYP2D6ALDH1A1LMNAMAPT | |
| SCHEMBL14069461 | 0.81 | EPHX2 (0.50) | CYP1A2CYP2D6ALDH1A1DRD2MGLL | |
| SCHEMBL31114636 | 0.80 | EPHX2 (0.57) | ALDH1A1LMNAMAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142337-A1 | Piperidine derivative and use thereof | AR, AHR, ARNT | CYP1A2 104/4885CYP2D6 252/4885ALDH1A1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.